Wider Q1 Loss, Lower Sales Drag ImmunoGen, Inc. (IMGN) Shares Lower
ImmunoGen (NASDAQ: IMGN) shares are lower after the company posted a quarterly net loss of $44.7 million, or $(0.51) per basic and diluted share, on revenues of $7.7 million vs. a net loss of $33.7 million, or $(0.39) per basic and diluted share, on revenues of $14.9 million the year prior. To view the full press release, visit: http://nnw.fm/Jgg6N About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing…